Owens & Minor, Inc.

is being recorded. I would now like to hand the conference over to your first speaker today, Jackie Marcus, Investor Relations.

Thank you, Operator. Hello, everyone, and welcome to the Owens & Miner third quarter 2024 earnings call. Our comments on the call will be focused on the financial results for the third quarter of 2024, as well as our outlook for 2024, both of which are included in today's press release. The press release, along with the supplemental slides, are posted on the investor relations section of our website. Please note that during this call, we will make forward-looking statements. The matters addressed in these statements are subject to risks and uncertainties, which could cause actual results to differ materially from those projected or implied here today. Please refer to our SEC filing for a full description of these risks and uncertainties, including the risk factors section of our annual report on Form 10-K and quarterly reports on Form 10-Q. In our discussion today, we will reference certain non-GAAP financial measures, and information about these measures and reconciliations to the most comparable GAAP financial measures are included in our press release. Today, I am joined by Ed Paseka, Olinpin Minors President and Chief Executive Officer, and John Leon, our Chief Financial Officer. I will now turn the call over to Ed.

Thank you, Jackie. Good morning, everyone, and thank you for joining us on the call today. I'd like to begin my remarks by acknowledging our teammates who were affected by hurricanes Helene and Milton in the southeastern portion of the United States. While our distribution facilities in the region were largely unaffected, our North Carolina kitting operations was unable to operate regularly due to disruptions in local and regional infrastructure, which caused some delays in deliveries. This kitting facility has been fully operational for the past few weeks. More importantly, our teammates and their families face significant, and in some cases, unimaginable personal losses. We are working with these teammates and their communities to help them recover. Turning to our financial and operational performance in the third quarter, we achieved top line growth across both segments, highlighted by exceptional demand for sleep supplies and diabetes in our patient direct segment. as well as strong same-store sales within products and healthcare services. Also in the quarter, we utilized some of our cash to reduce our overall debt and made additional investments in both segments to drive greater long-term efficiencies. I am pleased with our progress and I'm confident that we will maintain this momentum, leading to good sequential growth in cash flows in the upcoming quarter. Our products and healthcare service segment once again reported solid mid-single-digit revenue growth. This strong performance was driven by the strengthening of our existing customer relationships and the successful onboarding of new opportunities. Additionally, we continue to see prices stabilize in several of our key product categories, including gloves, more recently. Our improved top-line performance is a strong indication that our recent investments in our product and healthcare services segment were the correct and prudent choices to drive long-term growth. Turning to our Patient Direct segment, we are seeing positive returns from our investments earlier this year, which will drive growth through 2025. In the third quarter, we delivered mid-single-digit year-over-year top-line growth driven by strong demand across our served indications, most notably in our diabetes products and sleep supplies. Two examples of the investments to further improve our business were our sleep journey program as well as our enhancements to our revenue cycle process. The sleep journey is focused on improving the patient experience from onboarding new patients to making it easier for patients to obtain the supplies they need. Both of these programs are examples of us not resting on our success. We also made progress with respect to our balance sheets. having reduced total debt by nearly $200 million in the most recent quarter, using cash on hand and bringing our total year-to-date debt reduction to approximately $210 million. In the coming quarters, we are committed to continuing our debt repayment while also investing in our people, products, and processes. In mid-October, we shared an update to the Rotech Healthcare Holdings Acquisition Timeline. noting that we now expect the deal to close in the first half of 2025. In a highly regulated industry like healthcare, it is common for the Federal Trade Commission to request additional information and documentary materials for their review process. Our team is working closely with the FTC and Rotech to respond as quickly as possible, and we remain confident the deal will close in the months ahead. Most importantly, though, The addition of Rotech to our patient direct offering allows us to better support and serve patients, providers, and payers across the network. And we can more comprehensively serve patients with additional product offerings and improve service for patients with chronic conditions. In summary, we have delivered on our commitments for the first three quarters of 2024. Looking ahead, we are confident in our ability to demonstrate continued sequential growth and improving cash flows from the third to fourth quarter, positioning us well as we enter 2025. As we look ahead to 2025, we recognize that Chinese tariffs on key categories such as facial protection and gloves will impact our industry. However, our manufacturing footprint and sourcing profile is not dependent on China, unlike many of our competitors. This positions us well in the upcoming tariff environments. Before I turn the call over, I want to take a moment to congratulate John Leon on his appointment as Chief Financial Officer. John has been a critical member of the team here at Owens & Miner over the last seven years, and I look forward to working with him in his official role as CFO. With that, I will now turn the call over to John to discuss our third quarter financial performance in more detail. John?